VectivBio Holding AG
VECTNext catalyst
Apraglutide
Short Bowel Syndrome
Get an email about VECT's next catalysts
Track VectivBio Holding (VECT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 0 past
Apraglutide Phase 3 Est. Readout (STARS extend)
Primary completion for Apraglutide trial (NCT05018286) in Short Bowel Syndrome
SourceMarket Overview
Stock performance and key metrics
Apraglutide
Short Bowel Syndrome
FE203799
SBS - Short Bowel Syndrome
FE203799 GLP-2 analogue
Short Bowel Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Apraglutide | Phase 3 | Short Bowel Syndrome | - | - |
FE203799 | Phase 2 | SBS - Short Bowel Syndrome | - | - |
FE203799 GLP-2 analogue | Phase 2 | Short Bowel Syndrome | - | - |
Frequently asked questions
What is in VectivBio Holding AG's drug pipeline?β
CatalystAlert tracks 3 drug candidates in VectivBio Holding AG's (VECT) pipeline across Phase 3, Phase 2. Its lead program is Apraglutide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is VectivBio Holding AG's next FDA catalyst?β
VectivBio Holding AG's (VECT) next tracked catalyst is a Phase 3 readout expected Q4 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VECT biotech catalysts?β
Add VECT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow VectivBio Holding AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
